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ith the worldwide growing prev-
alence of obesity and type 2 dia-
betes, cardiovascular disease
(CVD), diabetic nephropathy, retinopa-
thy, and neuropathy as principal compli-
cations of diabetes are expected to
become a major public health challenge.
Diabetes accounts for at least double the
number of death rates compared with
otherwise healthy individuals. Hypergly-
cemia represents the hallmark of diabetic
metabolic changes, but whether antihy-
perglycemic treatment alone is sufﬁcient
to prevent cardiovascular and other or-
ganiccomplicationsintype2diabetesisa
matter of debate.
A recent meta-analysis of epidemio-
logical studies reported an 18% increase
in CVD risk for every 1% increase in A1C
(1). Two major studies have underlined
the importance of optimal glycemic con-
trol in reducing diabetes-related compli-
cations. The U.K. Prospective Diabetes
Study (UKPDS) showed that intensive
glycemic control (mean A1C below 7%)
by means of insulin or oral agents in type
2 diabetic patients reduces the relative
risk for microvascular outcomes by 25%
over a period of 10 years (relative risk re-
duction).Thereductioninmacrovascular
end points (myocardial infarction) was of
borderline signiﬁcance (16% relative risk
reduction, P  0.052) (2). The Diabetes
Control and Complications Trial/
Epidemiology of Diabetes Intervention
andComplications(DCCT/EDIC)trialre-
porteda50%reductioninCVDoutcomes
in type 1 diabetic patients treated inten-
sively over a period of 6.5 years and fol-
lowed for a further 12 years (3). In
contrast to these data, the intensive glu-
cose-lowering arm of the Action to Con-
trol Cardiovascular Risk (ACCORD)
trial—a major trial in type 2 diabetic pa-
tients—has been recently stopped be-
cause of increased mortality in this group
(4). The ACCORD trial was set up to test
three complementary medical treatment
strategies for type 2 diabetes to reduce
CVD morbidity and mortality. Aggressive
reduction of A1C below 6%, combined
increase in HDL cholesterol, and reduc-
tion of LDL cholesterol and lowering of
blood pressure (BP) were the main thera-
peutic targets. Because of safety concerns
after concise review of the available data
and recommendation by the safety mon-
itoring board, the intensive blood glucose
(BG)-lowering treatment arm was halted
in February 2008. There was a higher
death rate in the intensively treated
group, although a lower rate of primary
outcome events such as nonfatal myocar-
dial infarction was detected. The BP- and
lipid-loweringtrialswillbecontinuedun-
til June 2009.
The unexpected high mortality in the
group undergoing a treatment targeting
anA1Cbelow6%wasattributedtohypo-
glycemic episodes in older and plurimor-
bid patients, or to the adverse effects of a
particular drug or drug combination.
These data are not isolated, since the
2-yearfeasibilityphaseoftheVeteransAf-
fairs Cooperative Study on Glycemic
Control and Complications in Type II Di-
abetes Mellitus (VA-CSDM) found a non-
signiﬁcant increase in the risk for
cardiovascular events in the intensively
treated group (5).
Moreover, some combinations of
drugs (such as metformin and sulfonyl-
ureas)havepreviouslybeenconsideredto
be responsible for increased mortality,
suggestingthathyperglycemiashouldnot
be lowered at any price (6). Overall, at
leastthreeconclusionscanbedrawnfrom
these data: 1) lowering of BG in elderly
and plurimorbid patients should be per-
formed with caution, 2) combination
therapies should be rigorously consid-
ered,and3)theremaybeacertainthresh-
old beyond which lowering of BG may be
detrimental.
One further aspect that is under de-
bate in diabetes treatment is which of the
two aspects of hyperglycemia should be
mainly addressed: the preprandial or the
postprandial hyperglycemia? Several
studies have found that postprandial BG
correlates better with CV risk than does
fasting BG (7). The possible mechanisms
have been reviewed elsewhere (8). Con-
sistent with these ﬁndings, treatment of
postprandial hyperglycemia with acar-
bose in people with type 2 diabetes re-
sulted, according to a meta-analysis of
seven randomized studies, in a reduction
of CVD development by 35% (9). Evi-
dence from large interventional studies is
still lacking and the results of ongoing tri-
als are expected.
Fromalltheaforementioneddata,itis
obvious that controversy still exists as to
whether postprandial or fasting BG
should be targeted, and it is not exactly
known at which point the beneﬁt of low-
ering BG stops and the harm begins.
However, there is also another factor
beyond hyperglycemia that jeopardizes
the cardiovascular system of diabetic pa-
tients during the postprandial phase. Re-
cently, it has been shown that dietary
toxins signiﬁcantly impair endothelial
function in the postabsorptive state in
people with type 2 diabetes, an effect that
went beyond hyperglycemia and hyper-
triglyceridemia (10). Food toxins gener-
ated by heating consist of advanced
glycation end products (AGEs) and li-
poxidation end products, as well as other
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potential. The above-mentioned effects
were mostly reversible by changing the
method of meal preparation. Repeated,
even transient, impairment of endothelial
function is believed to result in perma-
nentchanges,animportantcontributorto
the development of atherosclerosis (11).
The role of AGEs in the development
of endothelial dysfunction (ED), athero-
sclerosis, and complications of diabetes
and aging has been emphasized (12).
Therefore, exogenous AGEs are believed
(but not yet conclusively demonstrated)
to play a role in the development of dia-
betes complications in addition to the
endogenously generated AGEs. The for-
mation of the latter is also stimulated by
conditions that occur in the postprandial
state such as hyperglycemia, oxidative
stress (13,14), or increase in AGE precur-
sors such as methylglyoxal (10). Methyl-
glyoxalisahighlyreactive-oxoaldehyde
metabolite of glucose degradation path-
ways and a precursor of AGEs and is ele-
vated in plasma of patients with type 2
diabetes (15). In vitro experiments re-
vealed that AGEs as well as methylglyoxal
increase tissue factor expression on the
surface of monocytes. Methylglyoxal en-
hances platelet-neutrophil aggregation
and the expression of MAC-1 on neutro-
phils and Apo2.7 on neutrophil mito-
chondria. These ﬁndings may contribute
to the understanding of diabetic throm-
bosis and the associated high cardiovas-
cular risk in diabetic patients (16). There
is evidence that because of its reactivity,
methylglyoxal might play a role in the eti-
ologyoftype2diabetes–relatedheartfail-
ure. In rats, methylglyoxal levels are
highest in the aorta and myocardium
compared with other tissues (17); in ad-
dition,methylglyoxalreactsnonenzymat-
icallywitharginineresiduesofproteinsto
form the AGEs argpyrimidine and N--
(5-hydro-5-methyl-4-imidazolon-2-yl)-
ornithine (methylglyoxal-H1). In
different cells, heat shock protein 27
(HSP27) was detected as a major argpyri-
midine containing protein. Comparing
human myocardial samples from patients
with cardiomyopathy and those with car-
diomyopathy plus type 2 diabetes, in re-
lation to nonfailing donor hearts, we
observed an increased argpyrimidine
modiﬁcation of HSP27 in left ventricular
myocardial samples of explanted hearts
from diabetic patients compared with in-
dividuals without type 2 diabetes. It was
postulated that these modiﬁcations are
consequences of the altered cardiac me-
tabolism found in type 2 diabetes and are
relevant for the stability of the myocardial
cytoskeleton. The impact of type 2 diabe-
tes on cardiomyopathy, termed “diabetic
cardiomyopathy,” is under debate (18).
We therefore believe that endog-
enously generated AGEs and precursors
act synergistically with the exogenous
AGEs to induce oxidative stress and lead
to the long-term cardiovascular and dia-
betes complications. The reduction in en-
dogenously generated AGEs goes beyond
thetreatmentofhyperglycemia,sincesev-
eral treatments that reduce oxidative and
carbonyl stress (e.g., angiotensin II recep-
tor inhibitors, antioxidants, aminoguani-
dine) have proven their efﬁcacy in
decreasingAGElevels(19).Mitigatingthe
exogenous AGE burden is also mostly in-
dependent from hyperglycemia (10,14).
Currently, it is widely believed that
CVD and mortality could be reduced in
diabetic patients, not only by reducing
hyperglycemia, but also by reducing risk
factors, such as dyslipoproteinemia and
increased BP.
Dyslipoproteinemia in type 2 diabe-
tes is characterized by at least three major
features: moderately increased LDL cho-
lesterol (women), increased triglycerides,
and decreased HDL cholesterol (20). The
importanceoftreatingdyslipidemiaindi-
abetes has been emphasized by the Adult
Treatment Panel III Guideline of the Na-
tional Cholesterol Education Program
(21),whereinLDLtargetshavebeensetto
below 100 mg/dl and even 70 mg/dl in
patients with diabetes and CVD (22). The
resultsofcholesterol-loweringtrialsinin-
dividuals with diabetes have been re-
viewed in detail elsewhere (20,23). The
Cholesterol Treatment Trialists’ Collabo-
rators reported that in their study popu-
lations of patients with type 2 diabetes,
they found a 9% proportional reduction
in all-cause mortality and a 21% propor-
tional reduction in major vascular events
for each reduction of 1 mmol/l in LDL
cholesterol (24).
Overall, there is strong evidence for
theimportanceofLDLloweringtoreduce
CVDindiabeticpatients.Althoughprom-
ising, the reduction in triglycerides and
increase in HDL cholesterol with ﬁbrates
in these patients remain to be demon-
strated (20).
Increased risk for CVD in parallel
with increased systolic and diastolic BP
has been suggested (25). In a subgroup of
people with type 2 diabetes within the
Systolic Hypertension in the Elderly Pro-
gram(SHEP),aposthocanalysisrevealed
that BP reduction resulted in a reduction
of major CVD events by 34% (26). There
also seems to be an additional beneﬁt if
lower diastolic BP values are targeted,
since a post hoc analysis of subjects with
diabetes from the Hypertension Optimal
Treatment (HOT) study showed that ma-
jor CVD events could be reduced by 51%
inthoserandomizedtoachieveadiastolic
BP of 80 mmHg, compared with indi-
viduals with a BP goal of 90 mmHg
(27). A recent meta-analysis emphasized
the importance of reducing BP in CVD
prevention in subjects with diabetes (28).
The Sixth Report of the Joint National
Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood
Pressure(JNCVI)(29)recommendedini-
tiationofantihypertensivetreatmentatBP
values of systolic 130 mmHg or dia-
stolic 85 mmHg. The ADVANCE (Ac-
tion in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation) trial, comprising 11,145 pa-
tients,addressedthetightregulationofBP
as an important risk factor of macrovas-
cular and microvascular complications in
type 2 diabetes.
The use of an ACE inhibitor in com-
bination with diuretic treatment for re-
ducing severe vascular events in patients
with diabetes, irrespective of initial BP
levels, or the use of other BP-lowering
drugs, was investigated. Compared with
patients assigned to placebo after a mean
of 4.3 years of follow-up, active therapy
reduced systolic and diastolic BP by 5.6
and 2.2 mmHg, respectively. The relative
risk of a major macrovascular or micro-
vascular event was signiﬁcantly reduced
by 9% (P  0.04). Reduction in macro-
vascular and microvascular events was
comparable, but failed to reach statistical
signiﬁcance. The relative risk of death
from CVD was reduced (relative risk re-
duction 18%; P  0.03) and the risk of
death from any cause was reduced (rela-
tive risk reduction 14%; P  0.03) (30).
As recently shown in the STENO-2
study, an intensiﬁed multifactorial inter-
vention using multiple drug combina-
tions aiming at tight glucose control,
renin angiotensin system blockade, anti-
coagulation, and lipid lowering, in addi-
tion to behavior modiﬁcation, led to a
sustainedbeneﬁcialeffectinreducingcar-
diovascular and microvascular events, as
well as mortality rates from cardiovascu-
lar and other causes (31). A total of 160
patients with type 2 diabetes and persis-
tent microalbuminuria were assigned to
receive either intensive or conventional
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withtimetodeathfromanycausedeﬁned
as a primary end point. The intensive
therapy was associated with a lower risk
of death from cardiovascular causes (haz-
ard ratio 0.43, P  0.04) and of cardio-
vascular events (hazard ratio 0.41, P 
0.001). Microvascular events, such as
end-stage renal disease or retinal inter-
vention, occurred at signiﬁcantly lower
rates in the intensively treated patients.
In summary, there is evidence that
the achievement of glycemic goals is dif-
ﬁcultandaccompaniedbyserioussideef-
fects that partly mask the beneﬁts. The
ACCORD trial found that attempts to
lower BG below an A1C of 6% were at the
expenses of higher mortality. It also be-
came obvious that treatment of hypergly-
cemia alone is not sufﬁcient to reduce CV
risk in diabetic patients and that treat-
ment of dyslipidemia and arterial hyper-
tension adds comparable protective
effects. The STENO-2 study elegantly
demonstrated this paradigm by showing
thatamultifactorialinterventionreduced,
inthelongterm,theriskofcardiovascular
and microvascular events in this
population.
Moreover, the postprandial phase is
an important therapeutic target, and be-
yond hyperglycemia and hypertriglyceri-
demia, oxidative stress and dietary toxins
have to be considered.
Therefore, physicians should focus
their efforts on lowering risk factors (lip-
ids, BP, and increased platelets adhesion)
and endeavor, especially in patients at
risk, to achieve an A1C between 7 and
7.5% with drugs that do not cause addi-
tional weight gain, have reduced side ef-
fects, and show a good cardiovascular
safety proﬁle.
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